Cancer
Scientists at the Research & Business Foundation Sungkyunkwan University have made a breakthrough in cancer treatment, filing a patent for a pharmaceutical composition that uses dendritic cells with a silenced Dab2 gene to prevent or treat cancer. The application, filed on November 7, 2014, and made available online on October
Cancer
Pharmacyclics, Inc. has initiated a new study, PCYC-1136-CA, to investigate the effectiveness of combining ibrutinib, a medication used to treat certain blood cancers, with MEDI4736, an investigational anti-PD-L1 immune checkpoint inhibitor being developed by AstraZeneca. The Phase Ib/II study aims to enroll approximately 109 patients in the U.S.
Cancer
Research from the University of British Columbia has shed light on the genetic characteristics of endometrial carcinomas, a type of cancer that affects the lining of the uterus. The study found that a proportion of these cancer cases are associated with deficient DNA mismatch repair (MMR), which can be identified
Cancer
A new cancer quality initiative and payment model, the Cancer Care Quality Program, is demonstrating positive outcomes in improving cancer care and reducing costs. Developed by Anthem, Inc., the program aims to promote evidence-based and cost-effective care for patients with cancer. As of June 1, the program is being implemented
Cancer
The American Society of Clinical Oncology (ASCO) has announced the launch of its first-ever clinical trial, the Targeted Agent and Profiling Utilization Registry (TAPUR) study, aimed at providing patients with advanced cancer access to molecularly-targeted cancer drugs and collecting "real-world" data on clinical outcomes. The trial will offer
Cancer
Pharmacyclics, Inc. has initiated a Phase Ib/II study to investigate the safety, tolerability, and effectiveness of combining ibrutinib (IMBRUVICA) with AstraZeneca's investigational anti-PD-L1 immune checkpoint inhibitor MEDI4736 in patients with relapsed or refractory (R/R) diffuse large B-cell lymphoma (DLBCL) or follicular lymphoma (FL). The study aims
Cancer
Researchers from Yonsei University have conducted a study to determine the effect of Daxx downregulation on anti-tumorigenesis induced by oncolytic adenovirus armed with TRAIL or TRAIL/shRNA of Bcl-xL genes. The study found that Daxx downregulation increases the anti-tumorigenic activity through enhancement of viral replication and cellular arrest with combination
Cancer
Cancer immunotherapy, designed to empower a patient's own immune system to eliminate cancer cells, has produced cure-like remissions in advanced cancers, including melanoma, lung cancer, and leukemia. The Cancer Research Institute (CRI) is hosting its third annual Cancer Immunotherapy Month in June to increase awareness and accelerate fundraising
Cancer
Researchers in Liaoning, China, have identified new histone modification markers in gastric cancer (GC) cells using chromatin immunoprecipitation microarray (ChIP-chip) analysis. The study aimed to determine the potential of these markers to distinguish between normal and GC cells, as well as their correlation with DNA methylation. The research suggests that
Cancer
Researchers have made a significant breakthrough in targeting the elusive cancer gene RAS, which has long been a challenge in cancer treatment. According to a study published in Clinical Cancer Research, recent technological advances and discoveries have greatly expanded our knowledge of the biology of oncogenic Ras and its role
Cancer
Researchers have developed a sensitive beta-galactosidase-targeting fluorescence probe for visualizing small peritoneal metastatic tumors in vivo. This innovative probe has the potential to revolutionize the diagnosis and treatment of ovarian cancer. The probe, designed by a team of scientists from Japan, utilizes a novel membrane-permeable HMRef-beta Gal molecule that exhibits
Cancer
Investigators at Leidos Biomedical Research, Inc. have discovered that two proteins, Fnip1 and Fnip2, play crucial roles in kidney tumor suppression in cooperation with Folliculin, a tumor suppressor for kidney cancer. The research, published in the Proceedings of the National Academy of Sciences, highlights the importance of these proteins in
